Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk

Colomba Falcone, Maria Paola Buzzi, Sara Bozzini, Chiara Boiocchi, Angela D'Angelo, Sandra Schirinzi, Jasmine Choi, Michael Ochan Kilama, Ciro Esposito, Massimo Torreggiani, Giuseppe Mancia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death in Western countries and is highly prevalent in patients with kidney disease. Traditional risk factors for CVD often accompany kidney dysfunction, and chronic kidney disease per se is considered an additional risk factor. Risk stratification for CVD remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for novel markers of cardiovascular risk, and several biomarkers have been suggested as candidates, together with C-reactive protein (CRP). The objective of the present study was to investigate the relationship between novel biomarkers of vascular inflammation (soluble form of the receptor for advanced glycation end products [sRAGE] and eotaxin-3) with CRP in a population of hypertensive patients at high cardiovascular risk. Methods: Plasma sRAGE, high-sensitivity CRP (hs- CRP) and eotaxin-3 were measured in 399 hypertensive patients (265 men, mean age 58 ± 8 years)with diabetes mellitus, metabolic syndrome or organ damage. Results: Plasma concentrations of sRAGE, eotaxin-3 and hs-CRP were not different between diabetic and nondiabetic subjects. Univariate analysis showed that plasma levels of sRAGE and eotaxin-3 were not associated with hs-CRP in either subgroup. Conclusion: Our study confirms the robust and widely studied role of CRP as an important marker of vascular inflammation. We also postulate the possible involvement of sRAGE and eotaxin, 2 novel biomarkers, in CVDs. On the basis of our results, we can put forward the hypotheses that hs-CRP, s-RAGE and eotaxin are reliable but unrelated cardiovascular risk markers.

Original languageEnglish
Pages (from-to)144-151
Number of pages8
JournalJournal of Nephrology
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

C-Reactive Protein
Cardiovascular Diseases
Biomarkers
Blood Vessels
Chemokine CCL24
Inflammation
Kidney Diseases
Advanced Glycosylation End Product-Specific Receptor
Chronic Renal Insufficiency
Cause of Death
Diabetes Mellitus
Kidney
Population

Keywords

  • Eotaxin-3
  • hs-CRP
  • Hypertension
  • sRAGE

ASJC Scopus subject areas

  • Nephrology

Cite this

Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. / Falcone, Colomba; Buzzi, Maria Paola; Bozzini, Sara; Boiocchi, Chiara; D'Angelo, Angela; Schirinzi, Sandra; Choi, Jasmine; Kilama, Michael Ochan; Esposito, Ciro; Torreggiani, Massimo; Mancia, Giuseppe.

In: Journal of Nephrology, Vol. 26, No. 1, 01.2013, p. 144-151.

Research output: Contribution to journalArticle

Falcone, C, Buzzi, MP, Bozzini, S, Boiocchi, C, D'Angelo, A, Schirinzi, S, Choi, J, Kilama, MO, Esposito, C, Torreggiani, M & Mancia, G 2013, 'Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk', Journal of Nephrology, vol. 26, no. 1, pp. 144-151. https://doi.org/10.5301/jn.5000122
Falcone, Colomba ; Buzzi, Maria Paola ; Bozzini, Sara ; Boiocchi, Chiara ; D'Angelo, Angela ; Schirinzi, Sandra ; Choi, Jasmine ; Kilama, Michael Ochan ; Esposito, Ciro ; Torreggiani, Massimo ; Mancia, Giuseppe. / Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. In: Journal of Nephrology. 2013 ; Vol. 26, No. 1. pp. 144-151.
@article{2b795bcb954f4deba9fa98b6ec8a3596,
title = "Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk",
abstract = "Background: Cardiovascular disease (CVD) is the leading cause of death in Western countries and is highly prevalent in patients with kidney disease. Traditional risk factors for CVD often accompany kidney dysfunction, and chronic kidney disease per se is considered an additional risk factor. Risk stratification for CVD remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for novel markers of cardiovascular risk, and several biomarkers have been suggested as candidates, together with C-reactive protein (CRP). The objective of the present study was to investigate the relationship between novel biomarkers of vascular inflammation (soluble form of the receptor for advanced glycation end products [sRAGE] and eotaxin-3) with CRP in a population of hypertensive patients at high cardiovascular risk. Methods: Plasma sRAGE, high-sensitivity CRP (hs- CRP) and eotaxin-3 were measured in 399 hypertensive patients (265 men, mean age 58 ± 8 years)with diabetes mellitus, metabolic syndrome or organ damage. Results: Plasma concentrations of sRAGE, eotaxin-3 and hs-CRP were not different between diabetic and nondiabetic subjects. Univariate analysis showed that plasma levels of sRAGE and eotaxin-3 were not associated with hs-CRP in either subgroup. Conclusion: Our study confirms the robust and widely studied role of CRP as an important marker of vascular inflammation. We also postulate the possible involvement of sRAGE and eotaxin, 2 novel biomarkers, in CVDs. On the basis of our results, we can put forward the hypotheses that hs-CRP, s-RAGE and eotaxin are reliable but unrelated cardiovascular risk markers.",
keywords = "Eotaxin-3, hs-CRP, Hypertension, sRAGE",
author = "Colomba Falcone and Buzzi, {Maria Paola} and Sara Bozzini and Chiara Boiocchi and Angela D'Angelo and Sandra Schirinzi and Jasmine Choi and Kilama, {Michael Ochan} and Ciro Esposito and Massimo Torreggiani and Giuseppe Mancia",
year = "2013",
month = "1",
doi = "10.5301/jn.5000122",
language = "English",
volume = "26",
pages = "144--151",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",
number = "1",

}

TY - JOUR

T1 - Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk

AU - Falcone, Colomba

AU - Buzzi, Maria Paola

AU - Bozzini, Sara

AU - Boiocchi, Chiara

AU - D'Angelo, Angela

AU - Schirinzi, Sandra

AU - Choi, Jasmine

AU - Kilama, Michael Ochan

AU - Esposito, Ciro

AU - Torreggiani, Massimo

AU - Mancia, Giuseppe

PY - 2013/1

Y1 - 2013/1

N2 - Background: Cardiovascular disease (CVD) is the leading cause of death in Western countries and is highly prevalent in patients with kidney disease. Traditional risk factors for CVD often accompany kidney dysfunction, and chronic kidney disease per se is considered an additional risk factor. Risk stratification for CVD remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for novel markers of cardiovascular risk, and several biomarkers have been suggested as candidates, together with C-reactive protein (CRP). The objective of the present study was to investigate the relationship between novel biomarkers of vascular inflammation (soluble form of the receptor for advanced glycation end products [sRAGE] and eotaxin-3) with CRP in a population of hypertensive patients at high cardiovascular risk. Methods: Plasma sRAGE, high-sensitivity CRP (hs- CRP) and eotaxin-3 were measured in 399 hypertensive patients (265 men, mean age 58 ± 8 years)with diabetes mellitus, metabolic syndrome or organ damage. Results: Plasma concentrations of sRAGE, eotaxin-3 and hs-CRP were not different between diabetic and nondiabetic subjects. Univariate analysis showed that plasma levels of sRAGE and eotaxin-3 were not associated with hs-CRP in either subgroup. Conclusion: Our study confirms the robust and widely studied role of CRP as an important marker of vascular inflammation. We also postulate the possible involvement of sRAGE and eotaxin, 2 novel biomarkers, in CVDs. On the basis of our results, we can put forward the hypotheses that hs-CRP, s-RAGE and eotaxin are reliable but unrelated cardiovascular risk markers.

AB - Background: Cardiovascular disease (CVD) is the leading cause of death in Western countries and is highly prevalent in patients with kidney disease. Traditional risk factors for CVD often accompany kidney dysfunction, and chronic kidney disease per se is considered an additional risk factor. Risk stratification for CVD remains suboptimal even after the introduction of global risk assessment by various scores. This has prompted the search for novel markers of cardiovascular risk, and several biomarkers have been suggested as candidates, together with C-reactive protein (CRP). The objective of the present study was to investigate the relationship between novel biomarkers of vascular inflammation (soluble form of the receptor for advanced glycation end products [sRAGE] and eotaxin-3) with CRP in a population of hypertensive patients at high cardiovascular risk. Methods: Plasma sRAGE, high-sensitivity CRP (hs- CRP) and eotaxin-3 were measured in 399 hypertensive patients (265 men, mean age 58 ± 8 years)with diabetes mellitus, metabolic syndrome or organ damage. Results: Plasma concentrations of sRAGE, eotaxin-3 and hs-CRP were not different between diabetic and nondiabetic subjects. Univariate analysis showed that plasma levels of sRAGE and eotaxin-3 were not associated with hs-CRP in either subgroup. Conclusion: Our study confirms the robust and widely studied role of CRP as an important marker of vascular inflammation. We also postulate the possible involvement of sRAGE and eotaxin, 2 novel biomarkers, in CVDs. On the basis of our results, we can put forward the hypotheses that hs-CRP, s-RAGE and eotaxin are reliable but unrelated cardiovascular risk markers.

KW - Eotaxin-3

KW - hs-CRP

KW - Hypertension

KW - sRAGE

UR - http://www.scopus.com/inward/record.url?scp=84877099525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877099525&partnerID=8YFLogxK

U2 - 10.5301/jn.5000122

DO - 10.5301/jn.5000122

M3 - Article

C2 - 23147687

AN - SCOPUS:84877099525

VL - 26

SP - 144

EP - 151

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 1

ER -